Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 2/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
| ▸ | SCD | O00767 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26834858 | 0.92 | DUT (0.41) | MEN1KMT2ADUTGRM2KCNH2 | |
| SCHEMBL30163044 | 0.83 | CPB2 (0.36) | MEN1KMT2AADAMTS5CPB2 | |
| SCHEMBL31132827 | 0.79 | DUT (0.38) | MEN1KMT2ADUTMAPK1AR | |
| SCHEMBL2282033 | 0.77 | CPB2 (0.45) | MEN1KMT2AGRM2KCNH2ADAMTS5 | |
| SCHEMBL30162824 | 0.77 | MEN1 (0.39) | MEN1KMT2AGRM2KCNH2ADAMTS5 | |
| SCHEMBL22748851 | 0.76 | DUT (0.40) | MEN1KMT2ADUT | |
| SCHEMBL21361934 | 0.76 | MEN1 (0.43) | MEN1KMT2AGRM2KCNH2ADAMTS5 | |
| SCHEMBL15775548 | 0.76 | MEN1 (0.43) | MEN1KMT2AGRM2KCNH2ADAMTS5 | |
| SCHEMBL17410494 | 0.76 | DUT (0.40) | DUT | |
| SCHEMBL21314975 | 0.75 | MEN1 (0.40) | MEN1KMT2AGRM2KCNH2ADAMTS5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | NANJING ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| EP-4273146-A1 | TRICYCLIC COMPOUND AND USE THEREOF | Nanjing Zaiming Pharmaceutical Co., Ltd. (CN) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
| WO-2022143864-A1 | TRICYCLIC COMPOUND AND USE THEREOF | 江苏先声药业有限公司 | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124454-A1 | TRICYCLIC COMPOUND AND USE THEREOF | MAT2A, MNAT1, KAT2A | MEN1 156/4885KMT2A 100/4885DUT 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.